









Markets
/
Stocks
/
nasdaq-naii
/

Natural Alternatives International Inc

NAII

3.120USD

-0.130-4.00%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

19.28MMarket Cap

LossP/E TTM



Natural Alternatives International Inc

3.120

-0.130-4.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

116 / 175

Overall Ranking

414 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 7.22M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -2.25, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.39M shares, decreasing 2.98% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 297.66K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.81, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 28.77M, representing a year-over-year increase of 14.44%, while its net profit experienced a year-over-year increase of 38.53%.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

5.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.16

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.24

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -2.34, which is -373.67% below the recent high of 6.40 and -38.33% above the recent low of -3.24.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 116/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.49, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 3.89 and the support level at 2.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.105

Sell

RSI(14)

38.830

Neutral

STOCH(KDJ)(9,3,3)

23.555

Neutral

ATR(14)

0.228

High Vlolatility

CCI(14)

-90.979

Neutral

Williams %R

77.959

Sell

TRIX(12,20)

-0.588

Sell

StochRSI(14)

66.432

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.149

Sell

MA10

3.289

Sell

MA20

3.507

Sell

MA50

3.595

Sell

MA100

3.439

Sell

MA200

3.654

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 54.83%, representing a quarter-over-quarter decrease of 0.09%. The largest institutional shareholder is James Simons, holding a total of 297.66K shares, representing 4.82% of shares outstanding, with 3.44% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

LeDoux (Mark A)

962.54K

-0.61%

Dimensional Fund Advisors, L.P.

428.54K

-0.12%

Caldwell Sutter Capital, Inc

420.89K

+2.04%

Renaissance Technologies LLC

Star Investors

304.16K

-1.65%

Mink Brook Asset Management LLC

294.92K

-1.70%

The Vanguard Group, Inc.

Star Investors

243.06K

Wolf (Kenneth Eugene)

131.99K

-5.42%

Morgan Stanley Smith Barney LLC

93.55K

-9.83%

Bridgeway Capital Management, LLC

120.25K

+0.03%

Dunn (Alan G)

91.21K

+9.61%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.47, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.55. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.